Skip to main content

Table 2 Medication usage in mild and moderate/severe seasonal allergic rhinitis patients

From: The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey

 

SAR severity

Mild

(n = 254)

Moderate/severe (n = 746)

Odds ratio (95 % CI)

P value

Taking medication, n (%)

230 (90.6)

718 (96.2)

2.68 (1.45, 4.89)

0.0004

Oral medications, n (%)

184 (80.0 %)

605 (84.3 %)

1.34 (0.89, 1.98)

0.1322

Cetirizine

82 (44.6)

313 (51.7)

1.33 (0.94, 1.89)

0.0885

Loratadine

61 (33.2)

195 (32.2)

0.96 (0.67, 1.39)

0.8153

Chlorphenamine

61 (33.2)

178 (29.4)

0.84 (0.58, 1.22)

0.3349

Pseudoephedrine

14 (7.6)

92 (15.2)

2.18 (1.19, 4.25)

0.0081

Phenylephrine

7 (3.8)

33 (5.5)

1.46 (0.62, 3.97)

0.3716

Acrivastine

20 (10.9)

82 (13.6)

1.29 (0.75, 2.28)

0.3420

Levocetirizine

0 (0)

19 (3.1)

–

0.011

Fexofenadine

10 (5.4)

38 (6.3)

1.17 (0.56, 2.68)

0.6741

Desloratadine

3 (1.6)

24 (4.0)

2.49 (0.74, 13.06)

0.1651

Other

17 (9.2)

57 (9.4)

1.02 (0.57, 1.93)

0.9408

Nasal sprays, n (%)

134 (58.3 %)

479 (66.7 %)

1.44 (1.05, 1.97)

0.0196

Fluticasone propionate

96 (71.6)

338 (70.6)

0.95 (0.60, 1.47)

0.8083

Beclomethasone

33 (24.6)

110 (23.0)

0.91 (0.57, 1.48)

0.6875

Mometasone

4 (3.0)

31 (6.5)

2.25 (0.77, 8.92)

0.1241

Fluticasone furoate

4 (3.0)

12 (2.5)

0.89 (0.26, 3.84)

0.8401

Flunisolide

1 (0.8)

12 (2.5)

3.42 (0.50, 147.15)

0.2116

Budesonide

2 (1.5)

10 (2.1)

1.41 (0.29, 13.36)

0.6602

Ipratropium bromide

0 (0)

5 (1.0)

–

0.29

Other

18 (13.4)

48 (10.0)

0.72 (0.39, 1.36)

0.2600

Oxymetazoline

9 (6.7)

39 (8.1)

1.23 (0.57, 2.97)

0.5871

Azelastine

25 (18.7)

106 (22.1)

1.23 (0.75, 2.10)

0.3860

Ocular medications, n (%)

72 (31.3 %)

275 (38.3 %)

1.36 (0.98, 1.90)

0.0552

Sodium cromoglicate

14 (19.4)

82 (29.8)

1.76 (0.91, 3.61)

0.0798

Antazoline

12 (16.7)

50 (18.2)

1.11 (0.54, 2.44)

0.7651

Xylometazoline

9 (12.5)

36 (13.1)

1.05 (0.47, 2.62)

0.8943

Azelastine

3 (4.2)

13 (4.7)

1.14 (0.30, 6.41)

0.8400

Olopatadine

3 (4.2)

17 (6.2)

1.52 (0.42, 8.29)

0.5137

Lodoxamide trometamol

1 (1.4)

9 (3.3)

2.40 (0.32, 106.74)

0.3950

Other

33 (45.8)

98 (35.6)

0.65 (0.37, 1.15)

0.1121

Co-medicating, n (%)

129 (56.1)

506 (70.5)

1.87 (1.36, 2.56)

0.0001

Reported reason for co-medicating, n (%)

 More effective nasal treatment

55 (42.6)

295 (58.3)

1.88 (1.25, 2.84)

0.0014

 More effective ocular treatment

54 (41.9)

209 (41.3)

0.98 (0.65, 1.48)

0.9089

 Faster nasal response

22 (17.1)

116 (22.9)

1.45 (0.86, 2.52)

0.1490

 Faster ocular

13 (10.1)

57 (11.3)

1.13 (0.59, 2.33)

0.7007

 Other

18 (19.0)

48 (9.5)

0.65 (0.35, 1.23)

0.1378

  1. SAR severity: paricipants with moderate/severe AR were defined as those who scored a rTNSS ≥8 out of 12, including a congestion score ≥2/3, when describing their ‘worst symptoms’. Participants with mild AR included all remaining patient
  2. SAR seasonal allergic rhinitis, CI confidence interval
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us